Dermira (NASDAQ:DERM) has been given a $20.00 price target by Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 146.61% from the company’s previous close. Cantor Fitzgerald also issued estimates for Dermira’s FY2018 earnings at ($4.63) EPS.
DERM has been the topic of a number of other reports. Needham & Company LLC lowered their price objective on shares of Dermira from $43.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, March 6th. Cowen set a $25.00 price objective on shares of Dermira and gave the company a “buy” rating in a research report on Monday, March 5th. Mizuho reaffirmed a “buy” rating on shares of Dermira in a research report on Friday, February 23rd. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 17th. Finally, Zacks Investment Research raised shares of Dermira from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $30.00.
Get Dermira alerts:
Dermira stock opened at $8.11 on Thursday. The company has a market capitalization of $438.57 million, a PE ratio of -1.85 and a beta of 1.50. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 2.19. Dermira has a fifty-two week low of $6.98 and a fifty-two week high of $31.59.
Dermira (NASDAQ:DERM) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). The firm had revenue of $0.30 million during the quarter. Dermira had a negative return on equity of 95.84% and a negative net margin of 8,823.69%. equities research analysts predict that Dermira will post -4.72 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. venBio Select Advisor LLC lifted its stake in Dermira by 125.5% in the first quarter. venBio Select Advisor LLC now owns 3,427,378 shares of the biopharmaceutical company’s stock valued at $27,385,000 after acquiring an additional 1,907,378 shares during the last quarter. Millennium Management LLC acquired a new stake in Dermira in the fourth quarter valued at approximately $25,084,000. Franklin Resources Inc. acquired a new stake in Dermira in the fourth quarter valued at approximately $24,820,000. Emerald Advisers Inc. PA acquired a new stake in Dermira in the fourth quarter valued at approximately $14,918,000. Finally, Eventide Asset Management LLC lifted its stake in Dermira by 169.4% in the first quarter. Eventide Asset Management LLC now owns 334,000 shares of the biopharmaceutical company’s stock valued at $2,669,000 after acquiring an additional 210,000 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.